Harrow (HROW) Income from Non-Controlling Interests (2019 - 2021)
Harrow's (HROW) quarterly Income from Non-Controlling Interests came in at $1000.0 in Q1 2021, up 106.25% year-on-year from $484.85 in Q1 2020, and up 112.5% quarter-over-quarter from -$8000.0 in Q4 2020.
Harrow (HROW) Income from Non-Controlling Interests (2019 - 2021) Analysis & Trends
Harrow's Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at $1000.0 for Q1 2021.
- On a quarterly basis, Income from Non-Controlling Interests rose 106.25% year-over-year to $1000.0 in Q1 2021; TTM through Mar 2022 was -$7000.0, a 84.44% increase from a year earlier, with the FY2020 full-year figure at -$62000.0, up 78.84% from the prior year.
- Income from Non-Controlling Interests climbed to $1000.0 in Q1 2021 per HROW's latest filing, from -$8000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $42000.0 in Q2 2019 and bottomed at -$161000.0 in Q3 2019.
- The 3-year median for Income from Non-Controlling Interests is -$15000.0 (2020), against an average of -$24444.4.
- Across the five-year window, Income from Non-Controlling Interests tumbled 164.0% in 2020 and jumped 106.25% in 2021, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$65000.0 in 2019, then soared by 87.69% to -$8000.0 in 2020, then jumped by 112.5% to $1000.0 in 2021.
- Per Business Quant, the three latest HROW Income from Non-Controlling Interests figures stand at $1000.0 (Q1 2021), -$8000.0 (Q4 2020), and -$15000.0 (Q3 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.97 Bn | 87.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.26 Bn | 30.32 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.15 Bn | 21.00 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.46 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.86 Bn | 16.55 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.66 Bn | 12.23 Bn | 785.00 Mn | - |
| 10 | Harrow | 1.46 Bn | 1.37 Bn | 27.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 1,000.00 |
| Dec 31, 2020 | -8,000.00 |
| Sep 30, 2020 | -15,000.00 |
| Jun 30, 2020 | -23,000.00 |
| Mar 31, 2020 | -16,000.00 |
| Dec 31, 2019 | -65,000.00 |
| Sep 30, 2019 | -161,000.00 |
| Jun 30, 2019 | 42,000.00 |
| Mar 31, 2019 | 25,000.00 |